secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0001193125-23-010947
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies CMO Suyash Prasad departs effective immediately
---------------------------------------------------------------------

- Chief Medical Officer Suyash Prasad separated from Taysha on Jan 12, 2023 by mutual agreement.
- Separation agreement terms not yet finalized; company to file further details later.
- No replacement named; CFO signed the 8-K filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523010947/0001193125-23-010947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523010947/d425122d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-010947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer